Overview

Triple Negative Breast Cancer Treatment Market Introduction

Triple-Negative Breast Cancer Treatment Market is forecasted to value over US$ 820 million by 2027 end and register a CAGR of over 4.5% from 2020 to 2027.

Triple-negative breast cancer is a type of cancer that does not have any receptors for hormones progesterone and estrogen. Triple-negative breast cancer does not respond to hormonal therapy and requires combines surgery.

Based on drug type the market is segmented into doxorubicin, cyclophosphamide, paclitaxel, docetaxel, cisplatin/carboplatin, and others. Doxorubicin is a chemotherapy drug used to treat acute lymphocytic leukemia, breast cancer, and bladder cancer. It slows down the growth of the cancer cells. Paclitaxel injection is used in the treatment of stomach cancer, prostate cancer, testicular cancer, and breast cancer. Doxorubicin can also interact with cyclophosphamide and paclitaxel. Based on the distribution channel, the market is bifurcated into hospital pharmacies and speciality cancer clinics. Speciality cancer clinics are the biggest end users owing to the easy availability of facilities.

The growing need for effective treatment against breast cancer is driving the growth of the market. A gradual increase in research and development alongside the adoption of new treatment types against cancer is expected to spur the size of the market.

Collaborations among prominent players in development and research of innovative and new drug are stimulating the size of the market. In addition, the robust pipeline of drugs in clinical development to diagnose triple-negative breast cancer treatment is also fueling the growth of the market. A huge trend spotted in the triple-negative breast cancer treatment is the evolution of nanotechnology. Nanotechnology has emerged as an efficient tool in the clinical management of triple-negative breast cancer.

North America currently holds a vast share of the market. The presence of prominent players alongside advanced healthcare infrastructure has expanded the size of the market. The Asia Pacific and Latin America regions have established vast potential opportunistic space for manufacturers thanks to an increase in treatment rate and rising prevalence of triple-negative breast. Increasing healthcare infrastructure in countries like India and China is expected to boost the growth of the market in the region in the coming years.

Established players of the market are:

Sanofi S.A, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Eli Lilly and Company, Mylan N.V and Novartis AG.

Triple Negative Breast Cancer Treatment Market

Triple-Negative Breast Cancer Treatment Market Segmentation:
By Drug Type
• Doxorubicin
• Cyclophosphamide
• Paclitaxel
• Docetaxel
• Cisplatin/Carboplatin
• Others

By Distribution Channel
• Hospital Pharmacies
• Specialty Cancer Clinics

By Region
• Europe
• North America
• APAC
• Latin America
• Rest of World

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on Global Triple-Negative Breast Cancer Treatment Market by Drug Type, by Distribution Channel, by Region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies